CA3204823A1 - Prmts inhibitors - Google Patents
Prmts inhibitorsInfo
- Publication number
- CA3204823A1 CA3204823A1 CA3204823A CA3204823A CA3204823A1 CA 3204823 A1 CA3204823 A1 CA 3204823A1 CA 3204823 A CA3204823 A CA 3204823A CA 3204823 A CA3204823 A CA 3204823A CA 3204823 A1 CA3204823 A1 CA 3204823A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- dihydrofuro
- methanone
- quinolin
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126416P | 2020-12-16 | 2020-12-16 | |
| US63/126,416 | 2020-12-16 | ||
| PCT/US2021/063540 WO2022132914A1 (en) | 2020-12-16 | 2021-12-15 | Prmts inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204823A1 true CA3204823A1 (en) | 2022-06-23 |
Family
ID=79927288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204823A Pending CA3204823A1 (en) | 2020-12-16 | 2021-12-15 | Prmts inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11845760B2 (https=) |
| EP (2) | EP4732837A2 (https=) |
| JP (2) | JP7487421B2 (https=) |
| KR (1) | KR20230121820A (https=) |
| CN (1) | CN116888120B (https=) |
| AR (1) | AR124369A1 (https=) |
| AU (1) | AU2021400942A1 (https=) |
| CA (1) | CA3204823A1 (https=) |
| CL (1) | CL2023001738A1 (https=) |
| CO (1) | CO2023008167A2 (https=) |
| CR (1) | CR20230310A (https=) |
| IL (1) | IL303451A (https=) |
| JO (1) | JOP20230138A1 (https=) |
| MX (1) | MX2023007192A (https=) |
| PE (1) | PE20231295A1 (https=) |
| TW (1) | TW202233183A (https=) |
| UY (1) | UY39565A (https=) |
| WO (1) | WO2022132914A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| UY39565A (es) * | 2020-12-16 | 2022-06-30 | Amgen Inc | Inhibidores de prmt5 novedosos |
| CA3230199A1 (en) * | 2021-08-30 | 2023-03-09 | Amgen Inc. | Process for synthesizing naphthyridine derivatives and intermediates thereof |
| CA3255376A1 (en) * | 2022-04-08 | 2023-10-12 | Amgen Inc. | CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS |
| WO2024002263A1 (zh) * | 2022-06-30 | 2024-01-04 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| EP4549440A4 (en) * | 2022-07-01 | 2026-04-22 | Cytosinlab Therapeutics Co Ltd | CLASS OF PRMT5 INHIBITORS AND THEIR USES |
| WO2024021957A1 (zh) * | 2022-07-26 | 2024-02-01 | 上海和誉生物医药科技有限公司 | 一种prmt5抑制剂及其制备方法和药学上的应用 |
| KR20250002472A (ko) * | 2022-08-03 | 2025-01-07 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | 질소 함유 삼중 축합고리 prmt5 억제제 및 이의 제조 방법 및 약학적 용도 |
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| EP4578862A1 (en) * | 2022-08-18 | 2025-07-02 | Medshine Discovery Inc. | Amide-containing heterocyclic derivatives and use thereof |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| EP4588920A4 (en) * | 2022-09-26 | 2026-01-28 | Shanghai Apeiron Therapeutics Company Ltd | NEW PRMT5 INHIBITOR AND ITS USE |
| CN118613482B (zh) * | 2022-09-26 | 2025-09-30 | 上海湃隆生物科技有限公司 | 新型prmt5抑制剂及其应用 |
| CN115677708B (zh) * | 2022-10-19 | 2024-11-29 | 深圳万知达企业管理有限公司 | 一种吡咯并喹喔啉的制备方法 |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| PE20251883A1 (es) * | 2022-12-05 | 2025-07-22 | Amgen Inc | Formas solidas de compuestos de naftiridina |
| CN120418246A (zh) * | 2022-12-23 | 2025-08-01 | 成都微芯药业有限公司 | 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用 |
| CN116332856A (zh) * | 2023-01-04 | 2023-06-27 | 荟达医药科技(上海)有限公司 | 一种4-哒嗪甲醇的合成方法 |
| CN118103373A (zh) * | 2023-01-18 | 2024-05-28 | 上海德琪医药科技有限公司 | Prmt5抑制化合物和其用途 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| IL322709A (en) * | 2023-02-28 | 2025-10-01 | Amgen Inc | Process for the synthesis of naphthyridine derivatives and their intermediates |
| CN121241054A (zh) * | 2023-04-14 | 2025-12-30 | 北京双鹤润创科技有限公司 | 氮杂环羰基稠环衍生物及其用途 |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024264503A1 (en) | 2023-04-23 | 2025-12-04 | Suzhou Genhouse Bio Co., Ltd. | Amide compound, pharmaceutical composition comprising same, and use thereof |
| WO2024234821A1 (zh) * | 2023-05-17 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| US11845749B1 (en) | 2023-07-13 | 2023-12-19 | King Faisal University | Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents |
| WO2025016323A1 (zh) | 2023-07-14 | 2025-01-23 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| WO2025026381A1 (zh) | 2023-08-02 | 2025-02-06 | 成都微芯药业有限公司 | 杂环炔基取代的酰胺衍生物、其制备方法及其应用 |
| TW202521525A (zh) | 2023-08-09 | 2025-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜芳基化合物、其製備方法及其在醫藥上的應用 |
| WO2025039979A1 (zh) | 2023-08-18 | 2025-02-27 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| WO2025076500A1 (en) * | 2023-10-06 | 2025-04-10 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025077856A1 (en) * | 2023-10-12 | 2025-04-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof |
| TW202519223A (zh) * | 2023-10-31 | 2025-05-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種吡啶衍生物及其在醫藥上的應用 |
| US20250154172A1 (en) * | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN119751486B (zh) * | 2023-12-29 | 2025-11-21 | 赛岚(杭州)生物医药科技有限公司 | 一类prmt5抑制剂及其用途 |
| WO2025166229A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) * | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025176054A1 (zh) * | 2024-02-20 | 2025-08-28 | 华润医药研究院（深圳）有限公司 | 三环杂环类化合物及其制备方法和医药用途 |
| TW202602453A (zh) * | 2024-03-14 | 2026-01-16 | 智擎生技製藥股份有限公司 | Mta協同性的prmt5抑制劑 |
| WO2025209511A1 (zh) * | 2024-04-03 | 2025-10-09 | 华润医药研究院（深圳）有限公司 | 杂环类化合物及其制备方法和医药用途 |
| WO2025215153A1 (en) * | 2024-04-10 | 2025-10-16 | Ryvu Therapeutics S.A. | Prmt5 inhibitors |
| WO2025218671A1 (en) * | 2024-04-16 | 2025-10-23 | Shanghai Apeiron Therapeutics Company Limited | Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use |
| WO2025257104A1 (en) | 2024-06-10 | 2025-12-18 | Sandvik Mining And Construction Tools Ab | Diamond and cemented carbide composite material |
| WO2025265110A1 (en) | 2024-06-21 | 2025-12-26 | Amgen Inc. | Oral pharmaceutical compositions comprising a naphthyridine compound |
| CN119552167B (zh) * | 2025-01-24 | 2026-02-03 | 赛岚(杭州)生物医药科技有限公司 | 一类用于抑制prmt5的化合物及其药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2703851T3 (es) | 2014-08-22 | 2019-03-12 | Merck Patent Gmbh | Indazoles |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US12552826B2 (en) * | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (en) * | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2021163344A1 (en) * | 2020-02-12 | 2021-08-19 | Amgen Inc. | Novel prmt5 inhibitors |
| UY39565A (es) * | 2020-12-16 | 2022-06-30 | Amgen Inc | Inhibidores de prmt5 novedosos |
-
2021
- 2021-12-15 UY UY0001039565A patent/UY39565A/es unknown
- 2021-12-15 EP EP26161361.6A patent/EP4732837A2/en active Pending
- 2021-12-15 IL IL303451A patent/IL303451A/en unknown
- 2021-12-15 TW TW110146964A patent/TW202233183A/zh unknown
- 2021-12-15 US US17/552,016 patent/US11845760B2/en active Active
- 2021-12-15 AR ARP210103508A patent/AR124369A1/es unknown
- 2021-12-15 CN CN202180093453.1A patent/CN116888120B/zh active Active
- 2021-12-15 MX MX2023007192A patent/MX2023007192A/es unknown
- 2021-12-15 JP JP2023535834A patent/JP7487421B2/ja active Active
- 2021-12-15 AU AU2021400942A patent/AU2021400942A1/en active Pending
- 2021-12-15 WO PCT/US2021/063540 patent/WO2022132914A1/en not_active Ceased
- 2021-12-15 KR KR1020237023776A patent/KR20230121820A/ko active Pending
- 2021-12-15 CA CA3204823A patent/CA3204823A1/en active Pending
- 2021-12-15 CR CR20230310A patent/CR20230310A/es unknown
- 2021-12-15 PE PE2023001893A patent/PE20231295A1/es unknown
- 2021-12-15 EP EP21847813.9A patent/EP4263545B1/en active Active
-
2023
- 2023-06-14 CL CL2023001738A patent/CL2023001738A1/es unknown
- 2023-06-14 JO JOJO/P/2023/0138A patent/JOP20230138A1/ar unknown
- 2023-06-22 CO CONC2023/0008167A patent/CO2023008167A2/es unknown
- 2023-11-06 US US18/502,780 patent/US20240092794A1/en active Pending
-
2024
- 2024-05-07 JP JP2024075101A patent/JP2024102236A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220194955A1 (en) | 2022-06-23 |
| JOP20230138A1 (ar) | 2023-06-14 |
| TW202233183A (zh) | 2022-09-01 |
| KR20230121820A (ko) | 2023-08-21 |
| AU2021400942A9 (en) | 2024-10-24 |
| PE20231295A1 (es) | 2023-08-22 |
| EP4263545B1 (en) | 2026-04-01 |
| CR20230310A (es) | 2023-09-01 |
| CN116888120B (zh) | 2026-04-28 |
| EP4732837A2 (en) | 2026-04-29 |
| CO2023008167A2 (es) | 2023-07-21 |
| CL2023001738A1 (es) | 2023-11-17 |
| US20240092794A1 (en) | 2024-03-21 |
| JP7487421B2 (ja) | 2024-05-20 |
| JP2023550530A (ja) | 2023-12-01 |
| JP2024102236A (ja) | 2024-07-30 |
| AR124369A1 (es) | 2023-03-22 |
| CN116888120A (zh) | 2023-10-13 |
| MX2023007192A (es) | 2023-07-03 |
| UY39565A (es) | 2022-06-30 |
| EP4263545A1 (en) | 2023-10-25 |
| IL303451A (en) | 2023-08-01 |
| AU2021400942A1 (en) | 2023-07-06 |
| US11845760B2 (en) | 2023-12-19 |
| WO2022132914A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3204823A1 (en) | Prmts inhibitors | |
| TWI766261B (zh) | 蛋白質酪胺酸磷酸酶抑制劑 | |
| AU2020341681B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| AU2019246753B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| CA3042960C (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
| EP4288435A1 (en) | Tricyclic-amido-bicyclic prmt5 inhibitors | |
| AU2017395023B2 (en) | Compounds and methods for CDK8 modulation and indications therefor | |
| EP4251624A1 (en) | Tricyclic carboxamide derivatives as prmt5 inhibitors | |
| CA3170321A1 (en) | Novel prmt5 inhibitors | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| AU2021289169B2 (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| KR20230104782A (ko) | Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 | |
| JP2019001715A (ja) | 三環性化合物 | |
| JP2016124810A (ja) | 新規縮合ピラゾール誘導体およびその医薬用途 | |
| JP6280130B2 (ja) | キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体 | |
| EA048318B1 (ru) | Ингибиторы prmt5 | |
| HK40091563B (zh) | 嘧啶酮类化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241220 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250103 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250103 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250103 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250523 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251124 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260119 |